Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 28;1(2):129–146. doi: 10.1016/j.jacasi.2021.08.003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Central Illustration — Consensus Pathway on Novel Therapy for Type 2 Diabetes

SGLT2 inhibitors include those with proven efficacy, including empagliflozin, canagliflozin, and dapagliflozin. GLP-1RAs include those with proven efficacy, including liraglutide, semaglutide, and dulaglutide. ASCVD = atherosclerotic cardiovascular disease; eGFR = estimated glomerular filtration rate (mL/min/1.73 m²); GLP-1 RA = glucagon-like peptide 1 receptor agonist; HF = heart failure; LVEF = left ventricular ejection fraction; PCE = Pooled Cohort Equation; RF = risk factor; SGLT2 i = sodium-glucose cotransporter 2 inhibitor.